TEST BANK FOR CLAYTON’S BASIC
PHARMACOLOGY FOR NURSES 19TH EDITION BY
MICHELLE J. WILLIHNGANZ, SAMUEL L. GUREVITZ,
BRUCE CLAYTON CHAPTER 1-48
written by
V
ASCORERS
, 1
Chapter 01: Drug Definitions, Standards, and Information Sources
V V V V V V V
Willihnganz: Clayton’s Basic Pharmacology for Nurses, 19th Edition
V V VV VV VV VV VV VV
MULTIPLE VCHOICE
1. Which Vname Videntifies Va Vdrug Vlisted VbyVthe VUS VFood
Vand VDrug VAdministration V(FDA)?
a. Brand
b. Nonproprietary
c. Official
d. Trademark
ANS: V C
The Vofficial Vname Vis Vthe Vname Vunder Vwhich Va Vdrug Vis
V listed V by Vthe V FDA. VThe V brand V name, Vor Vtrademark, Vis Vthe
Vname Vgiven Vto Va Vdrug V by V its V manufacturer. VThe
Vnonproprietary, Vor Vgeneric, V name V is Vprovided V by Vthe
VUnited VStates VAdopted VNames VCouncil.
DIF: Cognitive VLevel: VKnowledge REF: V p. V9
OBJ: V1NAT: VNCLEX VClient VNeeds VCategory: VSafe, VEffective
VCare VEnvironment VTOP: V Nursing VProcess VStep: V Assessment CON:
VPatient VEducation
2. Which Vsource Vcontains Vinformation Vspecific Vto Vnutritional Vsupplements?
a. USP VDictionary Vof VUSAN V &VInternational VDrug VNames
b. Natural VMedicines VComprehensive VDatabase
c. United VStates VPharmacopoeia/National VFormulary V(USP VNF)
d. Drug VInteraction VFacts
ANS: V C
United VStates VPharmacopoeia/National VFormulary Vcontains Vinformation Vspecific Vto
Vnutritional V supplements. VUSP VDictionary Vof VUSAN V & VInternational VDrug VNames V is Va
Vcompilation Vof Vdrug V names, Vpronunciation Vguide, Vand Vpossible V future VFDA Vapproved
Vdrugs; V it Vdoes V not Vinclude V nutritional V supplements. VNatural VMedicines VComprehensive
VDatabase Vcontains
evidence-based Vinformation Von Vherbal Vmedicines Vand Vherbal Vcombination Vproducts; Vit Vdoes
Vnot Vinclude V information Vspecific Vto Vnutritional V supplements. VDrug VInteraction VFacts
Vcontains Vcomprehensive V information Von Vdrug V interaction V facts; V it Vdoes V not Vinclude
Vnutritional Vsupplements.
DIF: Cognitive VLevel: VKnowledge REF: V p. V4 OBJ: V3
VNAT: V NCLEX VClient VNeeds VCategory: VPhysiological VIntegrity
TOP: V Nursing VProcess VStep: VAssessment CON: V Nutrition V|VPatient VEducation
3. Which Vdrug Vreference Vcontains Vdrug Vmonographs Vthat Vdescribe Vall Vdrugs Vin Va Vtherapeutic Vclass?
a. Drug VFacts Vand VComparisons
, 2
b. Drug VInteraction VFacts
c. Handbook Von VInjectable VDrugs
d. Martindale—The VComplete VDrug VReference
ANS: V A
Drug VFacts Vand VComparisons Vcontains Vdrug Vmonographs Vthat Vdescribe Vall Vdrugs
V in Va Vtherapeutic Vclass. VMonographs Vare Vformatted Vas Vtables Vto Vallow Vcomparison Vof
Vsimilar Vproducts, Vbrand V names, V manufacturers, Vcost Vindices, Vand V available Vdosage
V forms VOnline V version V is Vavailable.
DIF: Cognitive VLevel: VKnowledge REF: V p. V4 VTable V1.2
OBJ: V V 3 NAT: V NCLEX VClient VNeeds VCategory: VPhysiological VIntegrity
TOP: V Nursing VProcess VStep: VAssessment CON: V Safety V| VPatient VEducation V| VClinical VJudgment
4. Which Vdrug Vreference Vcontains Vmonographs Vabout VvirtuallyVeveryVsingle-entityVdrug
Vavailable Vin Vthe VUnited VStates Vand Vdescribes Vtherapeutic Vuses Vof Vdrugs, Vincluding
Vapproved Vand Vunapproved Vuses?
a. Martindale: VThe VComplete VDrug VReference
b. AHFS VDrug VInformation
c. Drug VReference
d. Drug VFacts Vand VComparisons
ANS: V B
AHFS VDrug VInformation Vcontains Vmonographs Vabout Vvirtually Vevery Vsingle-entity Vdrug
Vavailable Vin Vthe VUnited VStates Vand Vdescribes Vtherapeutic Vuses Vof Vdrugs, Vincluding Vapproved
Vand Vunapproved Vuses.
DIF: Cognitive VLevel: VKnowledge REF: V p. V4 VTable V1.2
OBJ: V V 3 NAT: V NCLEX VClient VNeeds VCategory:VPhysiological VIntegrity
TOP: V Nursing VProcess VStep: VPlanning CON: V Safety V| VPatient VEducation V| VClinical VJudgment
5. Which Vonline Vdrug Vreference Vmakes Vavailable Vto Vhealthcare Vproviders Vand Vthe Vpublic Va
Vstandard, Vcomprehensive, Vup-to-date Vlook Vup Vand Vdownloadable Vresource Vabout
Vmedicines?
a. American VDrug VIndex
b. American VHospital VFormulary
c. DailyMed
d. Drug VReference
ANS: V C
DailyMed Vmakes Vavailable Vto Vhealthcare Vproviders Vand Vthe Vpublic Va Vstandard,
Vcomprehensive, Vup-to-date Vlook Vup Vand Vdownloadable Vresource Vabout Vmedicines. VThe
VAmerican VDrug VIndex Vis V not Vappropriate V for Vpatient Vuse. VThe VAmerican VHospital
VFormulary V is V not Vappropriate V for Vpatient Vuse. VThe Vdrug Vreference V is V not Vappropriate V for
Vpatient Vuse.
DIF: Cognitive VLevel: VKnowledge REF: V p. V3 V| Vp. V4 OBJ: V3
VNAT: V NCLEX VClient VNeeds VCategory: VPhysiological VIntegrity
TOP: V NursingVProcess VStep: VImplementation
CON: V Safety V|VPatient VEducation V| VClinical VJudgment
6. Which Vlegislation Vauthorizes Vthe VFDA Vto Vdetermine Vthe VsafetyVof Va Vdrug Vbefore Vits Vmarketing?
a. Federal VFood, VDrug, Vand VCosmetic VAct V(1938)
b. Durham VHumphreyVAmendment V(1952)
, 3
c. Controlled VSubstances VAct V(1970)
d. Kefauver VHarris VDrug VAmendment V(1962)
ANS: V A
The VFederal VFood, VDrug, Vand VCosmetic VAct Vof V1938 Vauthorized Vthe VFDA Vto Vdetermine
Vthe Vsafety Vof Vall Vdrugs V before V marketing. VLater Vamendments Vand V acts Vhelped Vtighten
VFDA Vcontrol Vand Vensure Vdrug V safety. VThe VDurham VHumphrey V Amendment Vdefines Vthe
Vkinds Vof Vdrugs Vthat Vcannot Vbe Vused Vsafely Vwithout Vmedical Vsupervision V and Vrestricts Vtheir
Vsale Vto Vprescription V by Va V licensed Vpractitioner. VThe VControlled VSubstances VAct Vaddresses
Vonly Vcontrolled Vsubstances Vand Vtheir Vcategorization. VThe VKefauver VHarris VDrug
VAmendment Vensures Vdrug Vefficacy Vand Vgreater Vdrug Vsafety. VDrug V manufacturers Vare
Vrequired Vto Vprove Vto Vthe VFDA Vthe Veffectiveness V of Vtheir Vproducts Vbefore V marketing Vthem.
DIF: Cognitive VLevel: VKnowledge REF: V p. V5 VTable Vl.3
OBJ: V 5 NAT: VNCLEX VClient VNeeds VCategory: VPhysiological
VIntegrity VTOP: V Nursing VProcess VStep: V Assessment
CON: V Safety V| VPatient VEducation V| VEvidence V| VHealth VCare VLaw
7. Which Vclassification Vdoes Vmeperidine V(Demerol) Vfall Vunder?
a. I
b. II
c. III
d. IV
ANS: V B
Meperidine V(Demerol) Vis Va VSchedule VII Vdrug; Vit Vhas Va Vhigh Vpotential Vfor Vabuse Vand Vmay
Vlead Vto Vsevere Vpsychological Vand Vphysical Vdependence. VSchedule VI Vdrugs Vhave Vhigh
Vpotential Vfor Vabuse Vand V no Vrecognized V medical Vuse. VSchedule VIII Vdrugs Vhave V some
Vpotential V for Vabuse. VUse V may V lead Vto Vlow Vto Vmoderate Vphysical Vdependence Vor Vhigh
Vpsychological Vdependence. VSchedule VIV Vdrugs V have V low Vpotential V for Vabuse. VUse V may
V lead Vto V limited Vphysical Vor Vpsychological Vdependence.
DIF: Cognitive VLevel: VKnowledge REF: V p. V10 OBJ:
V2 VNAT: V NCLEX VClient VNeeds VCategory: VSafe, VEffective VCare
VEnvironment
TOP: V Nursing VProcess VStep: VAssessment CON: V Patient VEducation V| VAddiction V|VPain
8. Which Vaction Vwould Vthe VFDA Vtake Vto Vexpedite Vdrug Vdevelopment Vand Vapproval Vfor Van
Voutbreak Vof Vsmallpox?
a. List Vsmallpox Vas Va Vhealth Vorphan Vdisease.
b. Omit Vthe Vpreclinical Vresearch Vphase.
c. Extend Vthe Vclinical Vresearch Vphase.
d. Fast Vtrack Vthe Vinvestigational Vdrug.
ANS: V D
Once Vthe VInvestigational VNew VDrug VApplication Vhas Vbeen Vapproved, Vthe Vdrug Vcan Vreceive
Vhighest Vpriority Vwithin Vthe Vagency, Vwhich V is Vcalled V fast Vtracking. V A Vsmallpox Voutbreak
Vwould V become Va Vpriority Vconcern V in Vthe Vworld. V Orphan Vdiseases Vare V not Vresearched V in Va
Vpriority V manner. VPreclinical Vresearch V is V not Vomitted. VExtending Vany Vphase Vof Vthe Vresearch
Vwould V mean Va Vlonger Vtime Vto Vdevelop Va Vvaccine. VThe VFDA Vmust Vensure Vthat Vall Vphases Vof
Vthe Vpreclinical Vand Vclinical Vresearch Vphase V have V been Vcompleted V in Va Vsafe V manner.
DIF: Cognitive VLevel: VKnowledge REF: V V p. V7 OBJ: V 5
PHARMACOLOGY FOR NURSES 19TH EDITION BY
MICHELLE J. WILLIHNGANZ, SAMUEL L. GUREVITZ,
BRUCE CLAYTON CHAPTER 1-48
written by
V
ASCORERS
, 1
Chapter 01: Drug Definitions, Standards, and Information Sources
V V V V V V V
Willihnganz: Clayton’s Basic Pharmacology for Nurses, 19th Edition
V V VV VV VV VV VV VV
MULTIPLE VCHOICE
1. Which Vname Videntifies Va Vdrug Vlisted VbyVthe VUS VFood
Vand VDrug VAdministration V(FDA)?
a. Brand
b. Nonproprietary
c. Official
d. Trademark
ANS: V C
The Vofficial Vname Vis Vthe Vname Vunder Vwhich Va Vdrug Vis
V listed V by Vthe V FDA. VThe V brand V name, Vor Vtrademark, Vis Vthe
Vname Vgiven Vto Va Vdrug V by V its V manufacturer. VThe
Vnonproprietary, Vor Vgeneric, V name V is Vprovided V by Vthe
VUnited VStates VAdopted VNames VCouncil.
DIF: Cognitive VLevel: VKnowledge REF: V p. V9
OBJ: V1NAT: VNCLEX VClient VNeeds VCategory: VSafe, VEffective
VCare VEnvironment VTOP: V Nursing VProcess VStep: V Assessment CON:
VPatient VEducation
2. Which Vsource Vcontains Vinformation Vspecific Vto Vnutritional Vsupplements?
a. USP VDictionary Vof VUSAN V &VInternational VDrug VNames
b. Natural VMedicines VComprehensive VDatabase
c. United VStates VPharmacopoeia/National VFormulary V(USP VNF)
d. Drug VInteraction VFacts
ANS: V C
United VStates VPharmacopoeia/National VFormulary Vcontains Vinformation Vspecific Vto
Vnutritional V supplements. VUSP VDictionary Vof VUSAN V & VInternational VDrug VNames V is Va
Vcompilation Vof Vdrug V names, Vpronunciation Vguide, Vand Vpossible V future VFDA Vapproved
Vdrugs; V it Vdoes V not Vinclude V nutritional V supplements. VNatural VMedicines VComprehensive
VDatabase Vcontains
evidence-based Vinformation Von Vherbal Vmedicines Vand Vherbal Vcombination Vproducts; Vit Vdoes
Vnot Vinclude V information Vspecific Vto Vnutritional V supplements. VDrug VInteraction VFacts
Vcontains Vcomprehensive V information Von Vdrug V interaction V facts; V it Vdoes V not Vinclude
Vnutritional Vsupplements.
DIF: Cognitive VLevel: VKnowledge REF: V p. V4 OBJ: V3
VNAT: V NCLEX VClient VNeeds VCategory: VPhysiological VIntegrity
TOP: V Nursing VProcess VStep: VAssessment CON: V Nutrition V|VPatient VEducation
3. Which Vdrug Vreference Vcontains Vdrug Vmonographs Vthat Vdescribe Vall Vdrugs Vin Va Vtherapeutic Vclass?
a. Drug VFacts Vand VComparisons
, 2
b. Drug VInteraction VFacts
c. Handbook Von VInjectable VDrugs
d. Martindale—The VComplete VDrug VReference
ANS: V A
Drug VFacts Vand VComparisons Vcontains Vdrug Vmonographs Vthat Vdescribe Vall Vdrugs
V in Va Vtherapeutic Vclass. VMonographs Vare Vformatted Vas Vtables Vto Vallow Vcomparison Vof
Vsimilar Vproducts, Vbrand V names, V manufacturers, Vcost Vindices, Vand V available Vdosage
V forms VOnline V version V is Vavailable.
DIF: Cognitive VLevel: VKnowledge REF: V p. V4 VTable V1.2
OBJ: V V 3 NAT: V NCLEX VClient VNeeds VCategory: VPhysiological VIntegrity
TOP: V Nursing VProcess VStep: VAssessment CON: V Safety V| VPatient VEducation V| VClinical VJudgment
4. Which Vdrug Vreference Vcontains Vmonographs Vabout VvirtuallyVeveryVsingle-entityVdrug
Vavailable Vin Vthe VUnited VStates Vand Vdescribes Vtherapeutic Vuses Vof Vdrugs, Vincluding
Vapproved Vand Vunapproved Vuses?
a. Martindale: VThe VComplete VDrug VReference
b. AHFS VDrug VInformation
c. Drug VReference
d. Drug VFacts Vand VComparisons
ANS: V B
AHFS VDrug VInformation Vcontains Vmonographs Vabout Vvirtually Vevery Vsingle-entity Vdrug
Vavailable Vin Vthe VUnited VStates Vand Vdescribes Vtherapeutic Vuses Vof Vdrugs, Vincluding Vapproved
Vand Vunapproved Vuses.
DIF: Cognitive VLevel: VKnowledge REF: V p. V4 VTable V1.2
OBJ: V V 3 NAT: V NCLEX VClient VNeeds VCategory:VPhysiological VIntegrity
TOP: V Nursing VProcess VStep: VPlanning CON: V Safety V| VPatient VEducation V| VClinical VJudgment
5. Which Vonline Vdrug Vreference Vmakes Vavailable Vto Vhealthcare Vproviders Vand Vthe Vpublic Va
Vstandard, Vcomprehensive, Vup-to-date Vlook Vup Vand Vdownloadable Vresource Vabout
Vmedicines?
a. American VDrug VIndex
b. American VHospital VFormulary
c. DailyMed
d. Drug VReference
ANS: V C
DailyMed Vmakes Vavailable Vto Vhealthcare Vproviders Vand Vthe Vpublic Va Vstandard,
Vcomprehensive, Vup-to-date Vlook Vup Vand Vdownloadable Vresource Vabout Vmedicines. VThe
VAmerican VDrug VIndex Vis V not Vappropriate V for Vpatient Vuse. VThe VAmerican VHospital
VFormulary V is V not Vappropriate V for Vpatient Vuse. VThe Vdrug Vreference V is V not Vappropriate V for
Vpatient Vuse.
DIF: Cognitive VLevel: VKnowledge REF: V p. V3 V| Vp. V4 OBJ: V3
VNAT: V NCLEX VClient VNeeds VCategory: VPhysiological VIntegrity
TOP: V NursingVProcess VStep: VImplementation
CON: V Safety V|VPatient VEducation V| VClinical VJudgment
6. Which Vlegislation Vauthorizes Vthe VFDA Vto Vdetermine Vthe VsafetyVof Va Vdrug Vbefore Vits Vmarketing?
a. Federal VFood, VDrug, Vand VCosmetic VAct V(1938)
b. Durham VHumphreyVAmendment V(1952)
, 3
c. Controlled VSubstances VAct V(1970)
d. Kefauver VHarris VDrug VAmendment V(1962)
ANS: V A
The VFederal VFood, VDrug, Vand VCosmetic VAct Vof V1938 Vauthorized Vthe VFDA Vto Vdetermine
Vthe Vsafety Vof Vall Vdrugs V before V marketing. VLater Vamendments Vand V acts Vhelped Vtighten
VFDA Vcontrol Vand Vensure Vdrug V safety. VThe VDurham VHumphrey V Amendment Vdefines Vthe
Vkinds Vof Vdrugs Vthat Vcannot Vbe Vused Vsafely Vwithout Vmedical Vsupervision V and Vrestricts Vtheir
Vsale Vto Vprescription V by Va V licensed Vpractitioner. VThe VControlled VSubstances VAct Vaddresses
Vonly Vcontrolled Vsubstances Vand Vtheir Vcategorization. VThe VKefauver VHarris VDrug
VAmendment Vensures Vdrug Vefficacy Vand Vgreater Vdrug Vsafety. VDrug V manufacturers Vare
Vrequired Vto Vprove Vto Vthe VFDA Vthe Veffectiveness V of Vtheir Vproducts Vbefore V marketing Vthem.
DIF: Cognitive VLevel: VKnowledge REF: V p. V5 VTable Vl.3
OBJ: V 5 NAT: VNCLEX VClient VNeeds VCategory: VPhysiological
VIntegrity VTOP: V Nursing VProcess VStep: V Assessment
CON: V Safety V| VPatient VEducation V| VEvidence V| VHealth VCare VLaw
7. Which Vclassification Vdoes Vmeperidine V(Demerol) Vfall Vunder?
a. I
b. II
c. III
d. IV
ANS: V B
Meperidine V(Demerol) Vis Va VSchedule VII Vdrug; Vit Vhas Va Vhigh Vpotential Vfor Vabuse Vand Vmay
Vlead Vto Vsevere Vpsychological Vand Vphysical Vdependence. VSchedule VI Vdrugs Vhave Vhigh
Vpotential Vfor Vabuse Vand V no Vrecognized V medical Vuse. VSchedule VIII Vdrugs Vhave V some
Vpotential V for Vabuse. VUse V may V lead Vto Vlow Vto Vmoderate Vphysical Vdependence Vor Vhigh
Vpsychological Vdependence. VSchedule VIV Vdrugs V have V low Vpotential V for Vabuse. VUse V may
V lead Vto V limited Vphysical Vor Vpsychological Vdependence.
DIF: Cognitive VLevel: VKnowledge REF: V p. V10 OBJ:
V2 VNAT: V NCLEX VClient VNeeds VCategory: VSafe, VEffective VCare
VEnvironment
TOP: V Nursing VProcess VStep: VAssessment CON: V Patient VEducation V| VAddiction V|VPain
8. Which Vaction Vwould Vthe VFDA Vtake Vto Vexpedite Vdrug Vdevelopment Vand Vapproval Vfor Van
Voutbreak Vof Vsmallpox?
a. List Vsmallpox Vas Va Vhealth Vorphan Vdisease.
b. Omit Vthe Vpreclinical Vresearch Vphase.
c. Extend Vthe Vclinical Vresearch Vphase.
d. Fast Vtrack Vthe Vinvestigational Vdrug.
ANS: V D
Once Vthe VInvestigational VNew VDrug VApplication Vhas Vbeen Vapproved, Vthe Vdrug Vcan Vreceive
Vhighest Vpriority Vwithin Vthe Vagency, Vwhich V is Vcalled V fast Vtracking. V A Vsmallpox Voutbreak
Vwould V become Va Vpriority Vconcern V in Vthe Vworld. V Orphan Vdiseases Vare V not Vresearched V in Va
Vpriority V manner. VPreclinical Vresearch V is V not Vomitted. VExtending Vany Vphase Vof Vthe Vresearch
Vwould V mean Va Vlonger Vtime Vto Vdevelop Va Vvaccine. VThe VFDA Vmust Vensure Vthat Vall Vphases Vof
Vthe Vpreclinical Vand Vclinical Vresearch Vphase V have V been Vcompleted V in Va Vsafe V manner.
DIF: Cognitive VLevel: VKnowledge REF: V V p. V7 OBJ: V 5
